BCM
NVCR icon

Blume Capital Management’s NovoCure NVCR Stock Holding History

Blume Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,000
Closed -$20K – 226
2017
Q4 		$20K Hold
1,000
– – 0.01% 165
2017
Q3 		$20K Hold
1,000
– – 0.01% 168
2017
Q2 		$17K Hold
1,000
– – 0.01% 145
2017
Q1 		$8K Hold
1,000
– – ﹤0.01% 159
2016
Q4 		$8K Hold
1,000
– – ﹤0.01% 168
2016
Q3 		$9K Buy
1,000
+200
+25% +$1.82K 0.01% 158
2016
Q2 		$9K Buy
800
+100
+14% +$1.25K 0.01% 173
2016
Q1 		$10K Buy
+700
New +$10K 0.01% 180

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blume Capital Management's NVCR Position: Q1 2018 in Review

Blume Capital Management sold out of NovoCure (NVCR) in Q1 2018, closing a stake of 1,000 shares — an estimated $20K sold.

Blume Capital Management first reported a position in NVCR in Q1 2016 and held it in 8 quarters. The position peaked at $20K in Q4 2017. 129 funds tracked by Wall St. Rank hold NVCR as of Q1 2018.

  • Blume Capital Management reported no remaining NovoCure position as of Q1 2018 after selling out during the quarter.
  • Blume Capital Management sold 1,000 NovoCure shares in Q1 2018, an estimated $20K.
  • Blume Capital Management first reported a position in NovoCure in Q1 2016 and held it in 8 quarters.
  • Blume Capital Management's NovoCure position peaked at $20K in Q4 2017.
  • 129 funds tracked by Wall St. Rank held NovoCure as of Q1 2018.

Based on Blume Capital Management's 13F filing for Q1 2018, filed 4 May 2018.